Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
Recruiting now · Phase 2
Conditions studied: T-Cell Neoplasm, Lymphoproliferative Disorders
In brief
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
Key facts
- Study ID
- NCT04858256
- Run by
- University of Michigan Rogel Cancer Center
- People needed
- 100
- Starts
- 2023-03-29
- Expected to finish
- 2028-11-01
- Last updated by the study team
- 2026-01-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States (enrolling)
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan, United States (enrolling)
- Duke Cancer Institute — Durham, North Carolina, United States (enrolling)
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (enrolling)
- Moffitt Cancer Center — Tampa, Florida, United States
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.